Update – Early 2014 hope for EMA public hearings
This article was originally published in Scrip
Public hearings on marketed medicines could take place from the beginning of next year in Europe, the European Medicines Agency has clarified to Scrip. The agency hopes the hearings will both improve transparency and better include patient views about acceptable risk levels.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.